search
Back to results

Wound Healing Effects of HO/03/03 In Patients With Diabetic Neuropathic Plantar and Venous Ulcers, Pilot Study.

Primary Purpose

Diabetic Foot Ulcer, Venous Ulcer

Status
Completed
Phase
Phase 1
Locations
Israel
Study Type
Interventional
Intervention
HO/03/03
Sponsored by
HealOr
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetic Foot Ulcer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patients must satisfy all of the following inclusion criteria to be included in the study: be male or female over the age of 18; have a diabetic neuropathic plantar and/or venous ulcer; wound diameter <10cm; wound depth is no more than exposed muscle; have a current physical examination, which reveals no clinically significant abnormalities, except diabetes or diabetic ulcer/wound related condition be available for the entire study period, and be able and willing to adhere to protocol requirements; vascular inflow as measured by Doppler: ABI >= 0.7 have a debilitating wound over a period of 1 month prior to the experiment; if female of childbearing potential, must be using a reliable form of birth control; provide written informed consent prior to admission into the study. Exclusion Criteria: Patients will be excluded from the study if they meet any of the following exclusion criteria: have a body mass index (BMI) > 45; have a glycosylated hemoglobin (HbAlc) > 12.0%; have a history or presence of HIV or a clinically significant cardiac, gastrointestinal, endocrine, neurological, liver, or kidney disease; have any clinically significant illness during the 4 weeks prior to admission into the study, except diabetes type1 or type2; patients on concomitant medications that alter blood glucose levels (e.g., ACE inhibitors, lipid lowering agents, etc) must be on a stable dosage regimen for at least 4 weeks prior to entry into the study and the dosage must remain stable throughout the study; patients on chemotherapy; participation in a clinical study or use of an investigational drug within 30 days prior to admission to this study; are pregnant or lactating; visible bone exposure at wound site; have any signs of clinical infection in the wound (which could be linked to raised body temperature), necrosis, erythema or mild drainage; have any acute illness within 2 weeks prior to Screening; residing in a nursing facility and/or are bed-ridden (unable to come to receive treatment at the clinic);

Sites / Locations

  • Assaf Harofe Medical Center
  • Hadassah Ein Kerem Medical Center
  • Kaplan Medical Center

Arms of the Study

Arm 1

Arm Type

Active Comparator

Arm Label

Treatment arm

Arm Description

One Arm - Active Compound (HO/03/03)

Outcomes

Primary Outcome Measures

Safety

Secondary Outcome Measures

Time to Heal & Rate of Healing

Full Information

First Posted
June 19, 2006
Last Updated
August 16, 2007
Sponsor
HealOr
search

1. Study Identification

Unique Protocol Identification Number
NCT00338923
Brief Title
Wound Healing Effects of HO/03/03 In Patients With Diabetic Neuropathic Plantar and Venous Ulcers, Pilot Study.
Official Title
Wound Healing Effects of HO/03/03 In Patients With Diabetic Neuropathic Plantar and Venous Ulcers, Pilot Study.
Study Type
Interventional

2. Study Status

Record Verification Date
August 2007
Overall Recruitment Status
Completed
Study Start Date
June 2006 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
May 2007 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
HealOr

4. Oversight

5. Study Description

Brief Summary
This is a multicenter pilot study to assess the healing effects of HO/03/03 on diabetic neuropathic plantar and venous ulcers. HO/03/03 action mechanism involves the manipulation of keratinocyte and fibroblast migration and differentiation at the wound area. The primary end point of this study is assessment of safety in treating with HO/03/03 and the efficacy of the drug to promote wound closure of chronic wounds. The secondary end points are assessment time to closure and healing rate for the measurement of wound healing progression.
Detailed Description
This is a multicenter pilot study to assess the healing effects of HO/03/03 on diabetic neuropathic plantar and venous ulcers. Pretreatment phase: During a pretreatment phase that will last up to 14 days, all patients will receive the conventional treatment once a day at the discretion of the investigator. All wounds will be morphologically monitored by photo documentation daily and measurements of wound area once a week. Initial study visit: patients will begin treatment after completing all necessary demands in pre-treatment phase or after ruling out of all exclusion criteria. All wounds will be cleaned from previous treatment by surgical debridement and irrigation (saline). Treatment phase: Following the pre-treatment phase, wounds will be treated topically with HO/03/03 for 30 days. During this 30 day phase, patients will receive daily treatments with HO/03/03 either at home by a certified nurse or at the clinic. Wounds will be monitored by certified medical staff member as well as photo documentation. Then application of the treatment followed by a 15-minute rest. Finally wound will be dressed with a fresh dressing and monitoring of any adverse events. Patients will be administered HO/03/03 in addition to weight off-load Once a week wounds will be monitored by a physician: wounds size will be determined and documented. Patients will be evaluated for pain sensation at the wound area by filling a pain scoring questionnaire. Twice during the experiment patients will undergo blood profile, HbA1c, blood glucose, and urine samples testing at the initial and terminating visits. At the conclusion of the treatment phase the following will be completed: A physical examination; Collection of all blood and urine samples for clinical laboratory tests (dip sticks);

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetic Foot Ulcer, Venous Ulcer

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
22 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Treatment arm
Arm Type
Active Comparator
Arm Description
One Arm - Active Compound (HO/03/03)
Intervention Type
Drug
Intervention Name(s)
HO/03/03
Primary Outcome Measure Information:
Title
Safety
Time Frame
Treatment Period
Secondary Outcome Measure Information:
Title
Time to Heal & Rate of Healing
Time Frame
Treatment Period

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients must satisfy all of the following inclusion criteria to be included in the study: be male or female over the age of 18; have a diabetic neuropathic plantar and/or venous ulcer; wound diameter <10cm; wound depth is no more than exposed muscle; have a current physical examination, which reveals no clinically significant abnormalities, except diabetes or diabetic ulcer/wound related condition be available for the entire study period, and be able and willing to adhere to protocol requirements; vascular inflow as measured by Doppler: ABI >= 0.7 have a debilitating wound over a period of 1 month prior to the experiment; if female of childbearing potential, must be using a reliable form of birth control; provide written informed consent prior to admission into the study. Exclusion Criteria: Patients will be excluded from the study if they meet any of the following exclusion criteria: have a body mass index (BMI) > 45; have a glycosylated hemoglobin (HbAlc) > 12.0%; have a history or presence of HIV or a clinically significant cardiac, gastrointestinal, endocrine, neurological, liver, or kidney disease; have any clinically significant illness during the 4 weeks prior to admission into the study, except diabetes type1 or type2; patients on concomitant medications that alter blood glucose levels (e.g., ACE inhibitors, lipid lowering agents, etc) must be on a stable dosage regimen for at least 4 weeks prior to entry into the study and the dosage must remain stable throughout the study; patients on chemotherapy; participation in a clinical study or use of an investigational drug within 30 days prior to admission to this study; are pregnant or lactating; visible bone exposure at wound site; have any signs of clinical infection in the wound (which could be linked to raised body temperature), necrosis, erythema or mild drainage; have any acute illness within 2 weeks prior to Screening; residing in a nursing facility and/or are bed-ridden (unable to come to receive treatment at the clinic);
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Micha Rapoport, Dr.
Organizational Affiliation
Assaf Harofe Medical Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Leon Gilead, Dr.
Organizational Affiliation
Hadassah Ein Kerem Medical Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Zvi Landau, Dr.
Organizational Affiliation
Kaplan Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Assaf Harofe Medical Center
City
Beer Yaakov
ZIP/Postal Code
70300
Country
Israel
Facility Name
Hadassah Ein Kerem Medical Center
City
Jerusalem
Country
Israel
Facility Name
Kaplan Medical Center
City
Rechovot
Country
Israel

12. IPD Sharing Statement

Learn more about this trial

Wound Healing Effects of HO/03/03 In Patients With Diabetic Neuropathic Plantar and Venous Ulcers, Pilot Study.

We'll reach out to this number within 24 hrs